TSRL, Inc. is a preclinical accelerator that collaborates with academic researchers and other small businesses on the translation of their therapeutic concepts into clinical drug candidates. We are focused on developing the first pain-free transdermal microneedle (MN) patch, TSR-066, to provide a 5-day treatment course of zanamivir (ZAN) for the flu. Relenza®(ZAN), a difficult to use dry powder inhaler, requires twice a day inhalation and is contraindicated in patients with pre-existing lung conditions, a patient segment particularly vulnerable to flu infections and complications. Other oral competitors are notoriously plagued by resistant virus emergence. TSR-066 is a swellable microneedle drug-device combination product that is self-applied once by the patient, and delivers ZAN continuously over five days. The drug has years of human safety, and a 505(b)2 regulatory pathway will be available for the development and registration of TSR-066.
TSRL, Inc. is presenting as part of the NIH Innovation Zone.